Recipharm appoints General Manager for its new blow fill seal subsidiary in Kaysersberg, France

Yves Buelens, who has been plant manager since 2014, gains a promotion

Recipharm, a Swedish contract development and manufacturing organisation, has appointed Yves Buelens as General Manager for its wholly owned new subsidiary Kaysersberg Pharmaceuticals.

Buelens has a Masters in Pharmaceutical Sciences from the University of Brussels, Belgium and a specialisation as an Industrial Pharmacist (QP). He brings broad experience to the group, acquired in various roles in the pharmaceutical industry as well as in contract manufacturing organisations in Europe. Buelens has been plant manager for the Kaysersberg facility since 2014.

You may also like

Training & Education

Women in pharma: the battle against mansplaining continues

Prejudice in the workplace is an affliction suffered by many, but how can the industry be free from this nasty virus?
Manufacturing

Recipharm, Medspray and Resyca enter into license agreement to develop nasally-delivered soft mist drug products

Recipharm, Medspray and Resyca have entered an exclusive collaboration and licensing agreement to develop soft mist nasal delivery devices for single and combination drug products.
Manufacturing

Overcoming bio/pharmaceutical production hurdles: an industry insider perspective

From F-gas regulation to finance and from biologics to personalised medicines, the global drug production environment faces a number of challenges that could potentially stifle innovation and profitability. Dr Kevin Robinson (KSR) recently spoke to key players in the supplier and outsourcing community to better understand what services and solutions are available to keep the pipeline flowing
Manufacturing

Recipharm’s analytical lab brings testing capabilities to global markets

Fully cGMP/cGLP compliant, the 5,000 sqft lab will expand Recipharm’s existing analytical capabilities and provide support for biotech and pharma customers
Manufacturing

BES completes $4.8m refurb for Recipharm

The 4000 sqm facility, located in King’s Lynn, has seen an extensive redesign and refurbishment
Manufacturing

Recipharm extends commercial manufacturing for RedHill’s drug

Talicia is eligible for eight years of US market exclusivity under QIDP designation and its patent protection extends at least until 2034
Manufacturing

Recipharm expands services for pMDI propellants

The company's device development team recently completed a three-year Innovate UK (IUK) knowledge transfer partnership research programme with UK universities
Subscribe now